Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

CIDARA THERAPEUTICS INC (CDTX)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/17/2018 01/18/2018 01/19/2018 01/22/2018 01/23/2018 Date
7.2(c) 7.2(c) 7.3(c) 7.5(c) 7.35(c) Last
32 084 35 438 61 381 215 487 99 015 Volume
-0.69% 0.00% +1.39% +2.74% -2.00% Change
More quotes
Financials ($)
Sales 2017 0,21 M
EBIT 2017 -57,6 M
Net income 2017 -57,7 M
Finance 2017 62,7 M
Yield 2017 -
Sales 2018 0,88 M
EBIT 2018 -64,8 M
Net income 2018 -64,2 M
Finance 2018 76,9 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 416x
EV / Sales2018 85,6x
Capitalization 152 M
More Financials
Company
Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J.... 
More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CIDARA THERAPEUTICS INC
01/04 Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Ins..
2017 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Departure of Directors or..
2017 CIDARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
2017 CIDARA THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
2017 Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating N..
2017 Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
2017 CIDARA THERAPEUTICS : reports 3Q loss
2017 CIDARA THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
2017 Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Res..
2017 CIDARA THERAPEUTICS INC : Cidara Therapeutics, Inc. to Host Earnings Call
More news
Sector news : Bio Therapeutic Drugs
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
More sector news : Bio Therapeutic Drugs
Latest Tweets
05:57pGet the latest ratings for $ADRO $ETSY $VIRT $CDTX $KMPH in your inbox with M.. 
01/22$CDTX - Cantor Fitzgerald Analysts Give Cidara Therapeutics #CDTX a $15.00 Pr.. 
01/22Cantor Fitzgerald Analysts Give Cidara Therapeutics $CDTX a $15.00 Price Targ.. 
01/19Cantor Fitzgerald Gives a Buy Rating to Cidara Therapeutics $CDTX  
01/19Cidara Therapeutics Inc $CDTX Position Increased by JPMorgan Chase & Co. .. 
More tweets
Qtime:31
News from SeekingAlpha
01/10 ALTUM'S ANTIMICROBIAL UPDATE : SCYNEXIS, Cidara, Matinas
2017 ROTY EDITION 1 VOLUME 62 : (More) ASH Updates And Trades
2017 ROTY EDITION 1 VOLUME 59 : Updates And Trades
2017 CIDARA THERAPEUTICS : An Attractive Price For A Niche Opportunity With A High Pr..
2017 CIDARA THERAPEUTICS : This ROTY Holding Could Outperform Soon
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Technical analysis trends CIDARA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 13,9 $
Spread / Average Target 86%
EPS Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Matthew W. Onaitis CFO, Secretary, CAO & General Counsel
Taylor Sandison Chief Medical Officer
Theodore R. Schroeder Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS INC7.35%152
GILEAD SCIENCES13.04%106 315
VERTEX PHARMACEUTICALS5.41%40 948
REGENERON PHARMACEUTICALS-1.18%40 382
GENMAB13.75%11 797
BIOVERATIV INC92.49%11 230